Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means for the future of Cosentyx and Novartis’ inflammatory disease pipeline.

Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.

In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.